Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has reported Other Non-Current Liabilities for 4 consecutive years, with $35.6 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Other Non-Current Liabilities rose 2596.67% year-over-year to $35.6 million; the TTM figure through Jun 2024 stood at $35.6 million (up 2596.67% YoY), while the FY2023 annual figure was $1.2 million, down 14.18% from the prior year.
• Other Non-Current Liabilities rose to $35.6 million in Q2 2024 per RYTM's latest filing, from $34.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $35.6 million in Q2 2024 and bottomed at $1000.0 in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $8.6 million across 3 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities declined 16.98% — and 2024, when it surged 3459700.0%.
• Rhythm Pharmaceuticals' Other Non-Current Liabilities stood at $1.3 million in 2022, then declined by 14.18% to $1.2 million in 2023, then soared by 2995.3% to $35.6 million in 2024.
• Business Quant data shows RYTM's Other Non-Current Liabilities at $35.6 million in Q2 2024, $34.6 million in Q1 2024, and $1.2 million in Q4 2023.